No Prescription |
 |
 | ||
|
Postinor 2 Generic Levonorgestrel |
|
| ||
No Prescription » Prescription Drugs 13 » Postinor 2 Generic Levonorgestrel Postinor-2 is used as a form of emergency contraception (more commonly known as a morning after pill). Postinor-2 contains 750 micrograms of the drug levonorgestrel and also contains such ingredients as potato starch gelatin and talc. Postinor-2 is formulated to function in a manner similar to the female hormone progesterone allowing for prevention of pregnancy if taken within a reasonable period of time. Generally it is recommended that Postinor-2 be taken no later than three days after having unprotected sex. However it has proven to be more effective in cases where the treatment was started closer to the time of the sexual encounter. Postinor-2 is administered in two doses spaced out at twelve-hour intervals. It is important to note that if regurgitation occurs within two hours of taking the first dose it is imperative to immediately take the second pill in the series and contact a physician for a replacement. Also should the second dosage not be administered on time contact a physician and seek counsel on whether another round of treatment is needed. Buy Postinor 2 Generic Levonorgestrel and other Prescription Drugs 13 products online at Medstore. Buy Online at Medstore - Click Here!
About Postinor 2 Generic Levonorgestrel: Product Type: Prescription Drugs 13 Postinor 2 (Generic Levonorgestrel) Product Origin: Hungary Postinor 2 (Generic Levonorgestrel) Generic Levonorgestrel 0.75mg Generic Levonorgestrel Postinor 2
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
